Derm Panels & ABR Genes – Ipsum Diagnostics

DERM PANELS & ABR GENES

WHAT IS PCR?

PCR, short for Polymerase Chain Reaction, is a lab technique that quickly identifies infection causing organisms. Small quantities of DNA or RNA in a sample are amplified, and detected using a targeted approach for finding the pathogens (fungal, bacterial, viral, or parasitic).

Ipsum Diagnostic’s PCR technique more accurately and rapidly identifies potential pathogenic organisms and possible resistant genes than conventional culture methods. We can now identify the infection with greater sensitivity and specificity and recommend the medication that is most effective decreasing cost and morbidity.

Benefits of PCR over Traditional Culture

Ipsum’s pathogen assay uses the latest PCR technology to reliably analyze your patients sample.

Detection of the most relevant bacterial, fungal and viral pathogens
Patient specific antibiotic resistance
Results are not affected by antibiotic exposure

Highest level of sensitivity and specificity
99% accurate results in 48 hours or less from time of receipt
Work with our physicians to improve patient outcomes

Our Dermatologic Panels

Post-Op/Acute Wound Panel

Aeromonas hydrophila
Acinetobacter baumannii
Actinomyces israelii
Bacteroides fragilis
Campylobacter jejuni
Candida auris, albicans
Citrobacter freundii
Clostridium botulinum
Clostridium perfringens
Corynebacterium striatum
Eikenella corrodens
Enterococcus faecalis, faecium
Enterobacter spp.
Escherichia coli
Fusarium spp.
Fusobacterium necrophorum
Haemophilus influenzae
Herpes Simplex Virus 1 and 2 (HSV1&2)
Klebsiella spp.
Listeria monocytogenes
Methicillin-resistance Staphylococcus aureus (MRSA)
Morganella morganii
Mycobacterium marinum
Pasteurella multocida
Peptoniphilus spp.
Peptostreptococcus spp.
Prevotella spp.
Propionibacterium acnes
Proteus mirabilis
Proteus vulgaris
Pseudomonas aeruginosa
Serratia marcescens
Staphylococcus haemolyticus, lugdunensis
Staphylococcus aueus
Staphylococcus epidermidis
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Varicella zoster virus (VZV)
Vibrio cholerae, parahaemolyticus, vulnificus

Extended Derm Panel

Epidermophyton floccosum
Microsporum canis and gypseum
Trichophyton spp.
Malassezia fufur, pachydermatis
Candida auris, albicans, tropicalis, parapsalosis
Alternaria spp.
Aspergillus fumigatus, flavus
Fusarium spp.
Sporothrix schenckii
Sarcoptes scabiei
Corynebacterium minitissimum
Klebsiella oxytoca
Enterobacter spp.
Propionibacterium acnes
Proteus vulgaris
Pseudomonas aeruginosa
Methicillin-resistance Staphylococcus aureus (MRSA)
Streptococcus agalactiae (Group B Strep)
Streptococcus pyogenes (Group A Strep)
Herpes Simplex Virus Type 1 and Type 2
Varicilla-Zoster Virus
Mycobacterium marinum abscessus, fortuitum, chelonae

Antibiotic Resistance Genes

Quinolone Resistance:
QnrA
QnrB

Vancomycin Resistance:
vanA1
vanBF
vanC1

Carbapenem Resistance:
VIM
KPC
IMP-2 group
OXA-48

Macrolide Resistance:
ErmA
ErmB
ErmC

Methicillin Resistance:
MecA

Beta-lactam Resistance:

OXA-1

SHV

CTX-M

DERMATOLOGIC POLYMERASE CHAIN REACTION (PCR)

Why wait days for a bacterial panel and weeks for fungal culture results?

Ipsum Diagnostics can have your test results to you in less than 48 hours.

Real-time PCR utilizes highly specific assays for rapid, accurate profiling of polymicrobial infections. Let Ipsum provide your practice with quicker turn-around time for more effective treatment and superior patient care.

The advantages of PCR over traditional culture is unambiguous results that assist you with making all-important treatment decisions:

Faster, more accurate and precise results
Increased sensitivity and less prone to cross-contamination
Rapid results help minimize morbidity and reduce costs
DNA is extracted even on your most fragile specimens regardless of the viability of the swab

COMING SOON: Onychomycosis, Deep Fungal and Rate/Tropical Disease Panels

CONFIDENCE IN YOUR RESULTS

Ipsum’s unique pathogen target selection process and reporting process is provided by:

Vetted and updated by infectious disease and dermatology experts with 60+ years’ experience in SSTIs
Clinically relevant targets including common and emerging pathogens
Consistent with National/International Practice Guidelines”

Like our dermatology pathogen selection process, ABR gene selection and interpretation is provided by highly trained and experienced infectious disease and dermatology physicians to Ipsum’s clients.

Criteria for ABR gene selection:

1. The gene is prevalent in pathogens commonly found associated with skin infections seen in US based dermatology practices (i.e., no need for genes found only in rare nosocomial pathogens reported in institutions outside the US)

2. The gene confers resistance to antibiotics typically used by office-based dermatologists in the US (i.e., no need for aminoglycoside resistance targets)

3. The presence or absence of the gene impacts the clinician’s antibiotic choice and duration of therapy (i.e., no need for genes associated with virulence factors such as P-V leukocidin or genes important for hospital epidemiology but not clinical practice)

4. Validation data including sensitivity, specificity, and predictive values compared to conventional culture-based tests are available for the individual assays

Disclaimer and Limitations

This test was developed and its performance characteristics were determined by Ipsum Diagnostics LLC. The test has not been cleared or approved by the U.S. Food & Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1998 (CLIA) as qualified to perform high complexity clinical laboratory testing.

The assay is designed to detect pathogenic and non-pathogenic organisms as well as antibiotic resistance genes found in soft-skin and tissue wounds. Qualitative real-time polymerase chain reaction is used to detect the presence or absence of organisms and antibiotic resistance genes. The panel only tests for the specific organisms and antibiotic resistance genes included in the panel. The panel is limited to those specific organisms and antibiotic resistance genes. The presence of any organism or antibiotic resistance gene not included in the panel cannot be excluded. Antibiotic resistance genes may be expressed by more than one organism, including organisms not included in the panel.

The information contained in this test report is intended to be interpreted by a licensed healthcare professional to determine its clinical significance. A positive result does not rule out infection or co-infection with other bacteria, fungi, or viruses not tested by the panel.

Therapeutics

The listing of medications is for informational purposes only and is not intended or recommended as a substitute for medical advice, diagnosis, or treatment. The listing of medications does not imply the presence or severity of infection, or the need for treatment. Predicted susceptibility is specific to the organism(s) and/or antibiotic resistance gene(s) detected. Medications are based on standards, studies, guidelines, and reference material and are not created or developed by Ipsum Diagnostics LLC or any of its affiliates. All treatment decisions are the sole responsibility of the ordering physician or other qualified healthcare professional within the clinical context. Referral to an Infectious Disease Specialist may be indicated and is at the sole discretion of the ordering healthcare provider.

DERM PANELS COMING SOON